0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-100.80%PremiumJan 17, 2025Expiry Date2.51Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Akoya Biosciences Stock Discussion
Akoya Biosciences and Neracare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Tuesday, 10th December at 8:15 am
MARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma, to...
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
Akoya Biosciences (NASDAQ: AKYA) announces major innovations in spatial biology research at SITC 2024, introducing the PhenoCode Discovery IO60 panel and Mouse FFPE IO panel. The IO60 panel features 60 tumor and immunology markers, enabling comprehensive immune cell analysis with industry-leading throughput of over 16 samples per week. The ...
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
No comment yet